Pre-defined subgroups analyses of tower, a placebo-controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis

Authors
Category Primary study
JournalNeurology
Year 2013
This article has no abstract
Epistemonikos ID: f895c3228e491a5059e0578d66766d3ab1cd0ca9
First added on: Feb 05, 2025